NKGen Biotech, Inc. (NKGN) Stock

OTC Pink: NKGNClinical stage biotech company that focuses on the development and comercialization of autologous, allogeneic therapies.

NKGen Biotech stock price chart

NKGN interactive chart →

NKGN stock quote & key statistics

NKGen Biotech earnings per share

Income →
Earnings per share

NKGen Biotech revenue & net income

Income →
RevenueNet income

NKGen Biotech annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2023$0-$83.0M-$4.10
FY2022$77,000-$26.8M$0.21
FY2021$426,000-$23.3M-$0.05

Fiscal year ending December 31. Source: company filings via EODHD.

About NKGen Biotech, Inc.

NKGen Biotech, Inc. is a dynamic clinical-stage biotechnology firm specializing in the development and advancement of innovative natural killer (NK) cell therapies. Focused on both autologous and allogeneic approaches, as well as CAR-NK technologies, the company is committed to pioneering treatments that harness the natural capabilities of NK cells for therapeutic purposes.

Among its flagship products, SNK01 stands out as an autologous NK cell therapy designed to address neurodegenerative diseases. Additionally, SNK02, an allogeneic NK cell therapy, is currently undergoing Phase 1 clinical trials targeting refractory solid tumors, showcasing the company's diverse therapeutic applications and potential.

Established in 2017 and headquartered in Santa Ana, California, NKGen Biotech, Inc. originated as NKMAX America, Inc. before rebranding. Operating as a subsidiary of NKMAX Co., Ltd., the company benefits from synergies within the NKMAX network, leveraging shared expertise and resources to accelerate the development and commercialization of innovative NK cell therapies worldwide.

NKGen Biotech stock FAQ

What is the NKGen Biotech stock ticker symbol?

NKGen Biotech, Inc. trades on the OTC Pink under the ticker symbol NKGN.

What sector and industry is NKGen Biotech in?

NKGen Biotech, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does NKGen Biotech have?

NKGen Biotech, Inc. has about 26 full-time employees.

What were NKGen Biotech's revenue and earnings last fiscal year?

NKGen Biotech reported revenue of $0 and net income of -$83.0M in fiscal 2023, with earnings per share of -$4.10. Revenue declined 100.0% from the prior year.

When did NKGen Biotech go public?

NKGen Biotech stock began trading on July 13, 2021.

Biotechnology stocks

All Healthcare stocks →